|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Safety and efficacy of CPT-11/CF/5-Fu(IFL) versus FLF in previously untreaeed advanced or metastatic adoenocarcinoma of the stomach or gastroesophageal junction显示文摘 | Moehler MH Siebler J Hoehler T | 2003 | Proc AmSoc Clin Oncol2003，22，5： | 1 |
| 2 | Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer:a prospective multi-center biomarker-oriented phase Ⅱ study显示文摘 | Moehler M Mueller A Trarbach T Lordick F Seufferlein T Kubicka S | 2011 | Ann Oncol2011，22，： | 1 |
| 3 | Cetuximab with irinote- can, folinic acid and 5-fluorouracil as first-line treatment in ad- vanced gastroesophageal cancer: a prospective multi-center bin- marker- oriented phase l/study 显示文摘 | Moehler M Mueller T Trarbach T | 2011 | Ann Oncol2011，22，6： | 1 |
| 4 | Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial显示文摘 | Ralf-Dieter Hofheinz Frederik Wenz Stefan Post Axel Matzdorff Stephan Laechelt J?rg T Hartmann Lothar Müller Hartmut Link Markus Moehler Erika Kettner Elisabeth Fritz Udo Hieber Hans Walter Lindemann Martina Grunewald Stephan Kremers Christian Constantin | 2012 | Lancet Oncology2012，，6： | 1 |
| 5 | German S3-guideline “ diagnosis and treatment of esophagogastric cancer ”显示文摘 | MOEHLER M AL-BATRAN S E ANDUS T | 2011 | Z Gastroenterol2011，49，4： | 1 |
| 6 | Cetuximab with irino- tecan, folinic acid and 5-fluorouracil as first-line treatment in ad- vanced gastroesophageal cancer: a prospective multi-center bio- marker-oriented phase II study 显示文摘 | Moehler M Mueller A Trarbach T | 2011 | Ann Oncol2011，22，6： | 1 |
| 7 | Phase Ⅱ trial of mapatumumab,a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-indu cing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer显示文摘 | Trarbaeh T Moehler M Heinemann V | 2010 | Br J Cancer2010，102，3： | 1 |
| 8 | Molecular patho- genesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment显示文摘 | Klein B Seckinger A Moehler T | 2011 | Recent Results Cancer Res2011，183，： | 1 |
| 9 | Low expression of che- mokine receptor CCR5 in human colorectal cancer correlates with lymphatic dissemination and reduced CD8+ T-cell infiltration 显示文摘 | Zimmermann T Moehler M Gockel I | 2010 | Int J Colorectal Dis2010，25，4： | 1 |
| 10 | Reduced re- canalization rates of the great saphenous vein after endovenous la- ser treatment with increased energy dosing: definition of a threshold for the endovenous fluence equivalent 显示文摘 | PROEBSTLE T M MOEHLER T HERDEMANN S | 2006 | J Vasc Surg2006，44，4： | 1 |
| 11 | Safety and efficacy of CPT - 11/CF/5 - FU(IFL) versus FLF in previously unereaeed advanced or metzstatis adoenocarcinoma of the stomach or gastroesophageal junction 显示文摘 | Moehler MH Siebler J Hoehler T | 2003 | Proc Amsoc Clin Ooco12003，22，5： | 1 |
| 12 | Safety and efficacy of CPT-11/CF/5-Fu(IFL) versus FLF inpreviouslyuntreaeedadvanced or metastaticadoenocarcinoma of the stomach orgastroesophageal junction显示文摘 | Moehler MH Siebler J Hoehler T | | PmcAmSocClinOncol0，，： | 1 |
| 13 | Angiogenesis in hematologic malignancies显示文摘 | Moehler T M Neben K Ho A D | | 0，，12： | 1 |
| 14 | Phase Ⅱ trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer显示文摘 | Trarbach T Moehler M Heinemann V | 2010 | BrJ Cancer2010，102，3： | 1 |
| 15 | PhaseⅡtrial of mapatum umab,a fully hum an agonistic mono-clonal antibody that targets and activates the tumour nec-rosis factor apoptosis-inducing ligand receptor-1(TRAII-R1),in patients with refractory colorectal cancer显示文摘 | Trarbach T Moehler M Heinemann V | 2010 | Br JCancer2010，102，3： | 1 |
| 16 | Antiangio- genic therapy in hematologic malignancies显示文摘 | Moehler T M Hillengass J Goldschmidt H | 2004 | Curr Pharm Des2004，10，11： | 1 |
| 17 | Safety and efficacy CPT - 11/cF/5 - Fu (IFL) versus FLF in previously untreated advanced or metastatic adoenocarcmoma of the stomach or gastroesophaged junction 显示文摘 | Moehler MH Siebler J Hoehler T | 2003 | Proc Amsoc Clin Oncol2003，22，： | 1 |
| 18 | Synergy between an antiangiogenic integrin alphav antagonist and antibody-cytikine fusion protein eradicates spontaneous tumor metastases显示文摘 | Lode HN Moehler T Xiang R | 1999 | Proc Natl Acad Sci USA1999，96，4： | 1 |
| 19 | Cetuximab with irinotecan , folinic acid and 5-fluorouracil as firstline treatment in advancedgastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study显示文摘 | Moehler M Mueller A Trarbach T | 2011 | Ann Oncol2011，22，6： | 1 |
| 20 | Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase Ⅱ study 显示文摘 | Moehler M Mueller A Trarbach T | 2011 | Ann Oncol2011，22，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员